Buy signal, week 4 · US stocks
Recursion gains 10.2% and reclaims its 50-week average, new high fails on the close
Our view last week
Recursion's rebound stalls under its 50-week average, in the 3.9 area, which turned the price back: the week closes down 2.3% after last week's 19.7% gain, and sellers take charge of the weekly bar, with buying below 25% of volume. For Recursion stock, money flow still stays positive and the weekly MACD keeps improving. Our technical analysis calls for caution on one of the weekly buy signals open on US stocks.
This week's summary
Recursion closes the week up 10.2% and reclaims its 50-week average, in the 3.9 area, the level its rebound had stalled under a week ago. The week also brought a new 30-week high, in the 4.3 area, which the close did not confirm. For Recursion stock, money flow stays positive and the weekly MACD keeps improving, while an ADX of 8.5 says the trend has yet to gather strength: our technical analysis sees one of the weekly buy signals on US stocks moving forward.
IQS Phase
46
ordinary
Signal Strength
66
medium
Sizing
STANDARD
Ranking
#57 / 93
US stocks in progress
Trade P&L %
+13.50%
from signal to date, no stop loss
Recursion Pharmaceuticals (RXRX) weekly chart — EMA50 · MACD · VWAP
Weekly chart · EMA50 · MACD · VWAP · Source: TradingView
Rank position
ranks 57th among the 93 Longs already running for US stocks in our ranking, with a signal strength of 66 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -2.65% · monthly -3.91%
RXRX belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content